Recent international consensus has led to the renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) to reduce stigma, improve patient identification and reflect that MASLD is primarily a metabolic condition and not a liver condition. MASLD encompasses individuals who have hepatic steatosis and at least one cardiometabolic risk factor. Metabolic dysfunction-associated steatohepatitis (MASH) replaces non-alcoholic steatohepatitis (NASH). This session will cover the screening, diagnosis and management of MASLD in primary care, including the interpretation of abnormal liver blood tests.